Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | PPARA | Q07869 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | LSS | P48449 | 4/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.54 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.53 |
| ▸ | PRMT1 | Q99873 | 3/20 | 0.52 |
| ▸ | F2 | P00734 | 2/20 | 0.52 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.52 |
| ▸ | PLAU | P00749 | 1/20 | 0.52 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.52 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.52 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.52 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.52 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.52 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.52 |
| ▸ | F10 | P00742 | 1/20 | 0.52 |
| ▸ | PLG | P00747 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16414705 | 1.00 | GAA (0.61) | GAAPPARAL3MBTL1LSSTP53 | |
| SCHEMBL19024978 | 0.94 | GAA (0.58) | GAAPPARAL3MBTL1LSSTP53 | |
| SCHEMBL2588792 | 0.93 | PPARA (0.71) | GAAPPARAL3MBTL1LSSTP53 | |
| SCHEMBL9365095 | 0.93 | PPARA (0.71) | GAAPPARAL3MBTL1LSSTP53 | |
| SCHEMBL9361092 | 0.93 | PPARA (0.71) | GAAPPARAL3MBTL1LSSTP53 | |
| SCHEMBL9361207 | 0.93 | PPARA (0.71) | GAAPPARAL3MBTL1LSSTP53 | |
| SCHEMBL9360444 | 0.93 | PPARA (0.71) | GAAPPARAL3MBTL1LSSTP53 | |
| SCHEMBL9364419 | 0.93 | PPARA (0.71) | GAAPPARAL3MBTL1LSSTP53 | |
| SCHEMBL7681812 | 0.93 | LSS (0.64) | GAAPPARAL3MBTL1LSSTP53 | |
| SCHEMBL16418451 | 0.92 | GAA (0.57) | GAAPPARAL3MBTL1LSSTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281844-A1 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | SCHWARTZ JEAN-CHARLES (FR) | 2011-11-17 | — | — | US | disclosed |
| US-7910605-B2 | Non-imidazole alkylamines as histamine H3- receptor ligands and their therapeutic applications | SOCIETE CIVILE BIOPROJET (FR) | 2011-03-22 | — | — | US | disclosed |
| EP-2000462-A2 | Non-imidazole alkylamines as histamine H3-receptor ligands and their therapeutic applications | BIOPROJET (FR) | 2008-12-10 | — | — | EP | disclosed |
| US-7169928-B2 | central nervous system disorders; Alzheimer's disease; attention deficit disorders; cognition activators; psychological disorders; antidepressants | SOCIETE CIVILE BIOPROJECT (FR) | 2007-01-30 | — | — | US | disclosed |
| US-7138413-B1 | Administering tertiary amines, e.g., 3,3-Dimethylbutyl 3-piperidinopropyl ether, 3-Phenylpropyl 3-piperidinopropyl ether, or3-(4-Chlorophenyl)propyl 3-piperidinopropyl ether to treat cognitive disorders such as attention, wakefulness and memory disorders | SOCIETE CIVILE BIOPROJET (FR) | 2006-11-21 | — | — | US | disclosed |
| US-20060247223-A1 | Administering tertiary amines, e.g., 3,3-Dimethylbutyl 3-piperidinopropyl ether, 3-Phenylpropyl 3-piperidinopropyl ether, or3-(4-Chlorophenyl)propyl 3-piperidinopropyl ether to treat cognitive disorders such as attention, wakefulness and memory disorders | SCHWARTZ JEAN-CHARLES | 2006-11-02 | — | — | US | disclosed |
| US-20040220225-A1 | central nervous system disorders; Alzheimer's disease; attention deficit disorders; cognition activators; psychological disorders; antidepressants | SCHWARTZ JEAN-CHARLES (FR) | 2004-11-04 | — | — | US | disclosed |
| EP-1100503-B1 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H 3?-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ILE BIOPROJET SOC CIV (FR) | 2004-09-22 | — | — | EP | disclosed |
| EP-1428820-A1 | Non-imidazole alkylamines as histamine H-3-receptor ligands and their therapeutic applications | BIOPROJET (FR) | 2004-06-16 | — | — | EP | disclosed |
| EP-1100503-A2 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H 3?-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | SOCIETE CIVILE BIOPROJET (FR) | 2001-05-23 | — | — | EP | disclosed |
| EP-0982300-A2 | Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications | SOCIETE CIVILE BIOPROJET (FR) | 2000-03-01 | — | — | EP | disclosed |
| WO-2000006254-A2 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | SOCIETE CIVILE BIOPROJET (FR) | 2000-02-10 | — | — | WO | disclosed |
| EP-0978512-A1 | Non-imidazole aryloxy (or arylthio) alkylamines as histamine H3-receptor antagonists and their therapeutic applications | SOCIETE CIVILE BIOPROJET (FR) | 2000-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247223-A1 | Administering tertiary amines, e.g., 3,3-Dimethylbutyl 3-piperidinopropyl ether, 3-Phenylpropyl 3-piperidinopropyl ether, or3-(4-Chlorophenyl)propyl 3-piperidinopropyl ether to treat cognitive disorders such as attention, wakefulness and memory disorders | HRH3, HRH4, PNMT | GAA 3256/4885PPARA 1392/4885L3MBTL1 825/4885 |
| US-20040220225-A1 | central nervous system disorders; Alzheimer's disease; attention deficit disorders; cognition activators; psychological disorders; antidepressants | HTR1A, HRH4, HTR1D | GAA 2464/4885PPARA 2144/4885L3MBTL1 1621/4885 |
| US-20110281844-A1 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | HRH3, HRH4, HRH2 | GAA 4379/4885PPARA 1492/4885L3MBTL1 1955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.